Assenagon Asset Management S.A. lifted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 440.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 714,980 shares of the medical equipment provider’s stock after acquiring an additional 582,661 shares during the period. Assenagon Asset Management S.A.’s holdings in Lantheus were worth $79,320,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the stock. M&T Bank Corp purchased a new position in Lantheus in the 4th quarter worth $370,950,000. Farallon Capital Management LLC lifted its stake in Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after acquiring an additional 1,950,252 shares during the period. Norges Bank purchased a new stake in shares of Lantheus in the 4th quarter valued at $76,197,000. Freestone Grove Partners LP increased its stake in shares of Lantheus by 4,114.8% in the fourth quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock worth $40,497,000 after acquiring an additional 594,088 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in Lantheus by 686.1% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock worth $45,423,000 after purchasing an additional 522,678 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.
Wall Street Analysts Forecast Growth
LNTH has been the subject of several recent research reports. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a research report on Wednesday, July 29th. Mizuho dropped their price objective on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 29th. CJS Securities downgraded shares of Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Finally, Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $108.11.
Lantheus Stock Performance
LNTH opened at $100.95 on Friday. The company has a current ratio of 3.06, a quick ratio of 2.64 and a debt-to-equity ratio of 0.43. The firm’s 50-day moving average price is $104.09 and its 200 day moving average price is $87.98. Lantheus Holdings, Inc. has a twelve month low of $49.67 and a twelve month high of $111.86. The firm has a market capitalization of $6.57 billion, a PE ratio of 24.38 and a beta of -0.03.
Lantheus (NASDAQ:LNTH – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The firm had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The firm’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.57 earnings per share. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 4.5 EPS for the current fiscal year.
Lantheus Profile
Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.
The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.
See Also
- Five stocks we like better than Lantheus
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
